About This Leqembi FAQ
Leqembi is the first of (very likely) many forthcoming drugs that will be revolutionizing the landscape of early stage Alzheimer’s disease. With its traditional (full) FDA approval come new questions from our patients and community surrounding its availability, manufacturer, purchasing options, working mechanism, insurance coverage, and comparisons with other medications. Our doctors here at Isaac Health have compiled this FAQ to help provide clarity and direction as the health industry ramps up prescribing. Please check this page periodically for updates as the industry learns more about these new drugs.
When will Leqembi be available?
Leqembi is available now. Following traditional FDA approval, it is actively prescribed across the country and administered through certified outpatient infusion centers. Patients and families can consult with a cognitive specialist to determine whether they meet clinical criteria for treatment.
Which pharmaceutical company makes Leqembi?
Leqembi is a therapeutic antibody developed and manufactured by a pharmaceutical company called Eisai in collaboration with Biogen. Since 2014, Eisai and Biogen have dedicated extensive research and resources to create this groundbreaking drug for mild cognitive impairment and mild dementia due to Alzheimer’s disease, collectively known as “early Alzheimer’s disease”.
How do you access Leqembi?
Leqembi is a prescription medication and it is not available for purchase directly from pharmacies. To obtain Leqembi, individuals must consult with their healthcare providers or specialists who have the authority to prescribe and dispense the medication.
What does Leqembi do and how does it work?
Leqembi, also known as Lecanemab, is designed to slow down the progression of early Alzheimer’s disease. It works by targeting beta-amyloid plaques, which are abnormal protein deposits that accumulate in the brains of individuals with Alzheimer’s disease dementia. By reducing the buildup of these plaques, Leqembi aims to preserve cognitive function and delay the decline associated with the disease. Leqembi is administered through intravenous (IV) infusion exclusively at National Infusion Center Association (NICA) registered infusion centers.
Is Leqembi covered by insurance or Medicare?
Yes. Traditional Medicare Part B covers 80% of the cost of Leqembi for eligible individuals with early-stage Alzheimer’s disease who meet clinical criteria and are enrolled in a CMS-facilitated registry. Supplemental insurance plans, including Medigap and certain commercial policies, frequently cover the remaining 20% of out-of-pocket expenses. Our care navigators at Isaac Health work directly with families and insurance providers to verify exact coverage, review eligibility requirements, and coordinate enrollment.
What’s the difference between Leqembi and Donanemab?
Leqembi (lecanemab) and Kisunla (donanemab) are both FDA-approved antibody therapies designed to slow clinical decline in early Alzheimer’s disease. While both work by clearing abnormal amyloid plaques from the brain, they target plaques at slightly different stages and follow distinct dosing schedules. Because medical eligibility, administration schedules, and safety monitoring protocols vary between the two treatments, consulting with a cognitive neurologist is essential to identify which therapy fits your clinical profile.
Navigating new Alzheimer’s treatments can feel complex, but our clinical specialists are here to guide you. Schedule a consultation with our care team to review whether you or your family member meet clinical criteria. If you are already an active Isaac Health patient, you can message your provider directly through the patient portal to discuss treatment options.
Please note: The information provided here is for general informational purposes only and should not replace professional medical advice. Consultation with healthcare professionals is essential for personalized guidance and decision-making regarding treatment options.
